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Atrial ﬁbrillation (AF) represents the most common arrhyth-
ia, and it substantially increases the risk of stroke and death. The
revalence of AF is gradually increasing in Japan, as the popula-
ion ages [1]. Coronary artery disease (CAD) is also prevalent among
lderly people, and thus there are many patients who have both dis-
rders. Furthermore, AF and CAD share common mechanistic back-
rounds; long-lasting injuries in the atrial or arterial wall due to
emodynamic or metabolic stress are the underlying mechanisms.
Patients with AF more often have concomitant CAD, compared
ith healthy sinus rhythm controls [2,3], and patients with
therosclerosis more often have concomitant AF [4]. Furthermore,
atients with acute coronary syndrome showed worse outcomes if
hey had concomitant AF; in-hospital, 30-day, and 1-year adverse
utcome [5].
However, there has been limited information focusing on the
ssociation of AF and CAD in Japanese patients. In this large-scale
ong-term registry of patients with any kind of cardiovascular dis-
ase in a single center in an urban district of Japan, Senoo et al.
arried out retrospective surveillance of the prevalence and prog-
osis of CAD in patients with AF [6].
revalence of CAD in AF patients
In this paper [6], the prevalence of CAD in AF patients was
eported to be 6.4%, which is much lower than reports from
estern countries (18–34%, as stated in the paper), and also even
ower than other studies in Japan: 10.1% in the J-RHYTHM registry
7], 15.0% in the Fushimi AF Registry [8], and 19% in the Hokuriku
F trial [9]. However, the lower prevalence in the present study is
erhaps mainly due to the younger age of the registered patients
n this study (63.2 years in this study, 69.7 years in the J-RHYTHM
egistry, 74.2 years in the Fushimi AF Registry, and 72 in the
okuriku AF trial). Since the patients were enrolled from one of the
ost specialized cardiovascular centers of Japan, those patients
ere supposed to undergo comprehensive assessment of CAD,
nd thus it is unlikely that CAD was underdiagnosed. The lower
revalence of CAD in Japanese patients compared with Western
DOI of original article: http://dx.doi.org/10.1016/j.jjcc.2013.08.007.
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.09.010countries is, as the authors discussed in the paper, most likely to
be attributed to the differences in patients’ risk proﬁles. Especially
in the elderly generation, differences in the life-style including the
status of diet or nutrition between Japan and Western countries
are more distinct.
Incidence of coronary events in AF patients
There has been limited information regarding the incidence of
coronary events in AF patients, and the data are varied among stud-
ies, since the selection criteria (and thus the risk proﬁles) of the
patients or the deﬁnition of coronary events were heterogeneous.
This makes it difﬁcult to make a precise comparison across stud-
ies. In this paper by Senoo et al., the incidence rate of coronary
events was 1.9%/year, under the deﬁnition of “coronary events” as
hospitalization for myocardial infarction, unstable angina, or stable
angina. The actual distribution of each event is not indicated, but
the incidence of acute coronary syndrome (myocardial infarction
or unstable angina) is assumed to be substantially lower than this
value. The international large-scale randomized trials of novel oral
anticoagulants in AF patients reported as follows: 0.53% (myocar-
dial infarction) in the warfarin arm of the RE-LY trial [10], not
available in the ROCKET-AF trial [11], and 0.61% (myocardial infarc-
tion) in the warfarin arm of the ARISTOTLE trial [12]. The registry
studies of Japanese AF patients reported as follows: not available in
the J-RHYTHM registry [7], 0.4% (myocardial infarction) in Fushimi
AF Registry (preliminary data reported at the European Society of
Cardiology congress 2013 [13]), not available in the Hokuriku AF
trial [9]. The REACH registry reported a much higher number: 1.36%
non-fatal myocardial infarction and 5.95% unstable angina in AF
patients [4]. However, in the REACH registry, patients with high-
risk proﬁles (either established atherosclerotic disease or ≥3 risk
factors for atherosclerosis) were enrolled, but low-to-intermediate
risk patients were not included. The incidence of coronary events
is varied depending on the risk proﬁles of each patient population,
but the presence of CAD should carefully be watched during the
management of any AF patients.
CHADS2 score to predict coronary event
CHADS2 score is a well-established risk stratiﬁcation scheme
for the prediction of stroke in patients with AF [14], but it was also
reported to be useful, to some extent, for the prediction of coro-
nary events [4]. Also in this study, there was a signiﬁcant linear
association between CHADS2 score and annual coronary events.
However, the independent predictors of the incidence of coronary
events were limited to a history of CAD and older age. AF and CAD
vier Ltd. All rights reserved.
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hare a number of common backgrounds, but the pathogenesis and
he triggers of acute events may  be different.
oncomitant use of anti-thrombotic therapy in patients
ith AF and CAD
Anti-thrombotic therapy is indicated for the treatment of both
F and CAD. Oral anticoagulant (OAC) therapy is the mainstay
f treatment for AF patients at risk for stroke. Patients with AF
ho have concomitant CAD may  be put on antiplatelet drug (APD)
herapy in addition to OAC. However, the incremental beneﬁt of
PD added to OAC in patients with AF is unclear. Indeed, the
se of OAC + APD was independently associated with signiﬁcantly
ncreased risk for bleeding compared with the use of OAC alone.
o date, there have been limited data available to deﬁne current
atterns of use of concomitant APD along with OAC in AF patients.
urthermore, the risks of such combinations in community practice
emain poorly deﬁned.
The WOEST study is an open-label, multicenter trial in patients
ho require OAC and APD after stent implantation by percutaneous
oronary intervention [15]. Patients taking warfarin (controlled
y monitoring of international normalized ratio) were randomly
ssigned to receive warfarin plus clopidogrel alone (double ther-
py) or plus clopidogrel and aspirin (triple therapy). As a result,
arkedly fewer bleeding episodes were seen with double ther-
py than with triple therapy. Additionally, mortality at 1 year, a
econdary endpoint, was signiﬁcantly lower with double therapy
han with triple therapy. This trial raised the possibility that a
ess is more strategy may  be favorable among AF patients on OAC.
espite the increasing attention to the excess risk of bleeding in
he combination therapy, the therapeutic regimens are not always
ppropriate; the ORBIT-AF registry recently reported that many AF
atients receiving OAC are often treated with APD, even when they
o not have atherosclerotic vascular diseases [16]. The WOEST trial
as under-powered to draw deﬁnite conclusions, but adequately
owered, prospective clinical studies of these regimens are warr-
nted to assess the beneﬁt or harm of such strategies. Physicians
eed to assess the severity or activity of both AF and CAD, and care-
ully weigh whether the potential beneﬁts of adding APD are worth
he risk among patients with AF on OAC.
ummary
AF and CAD resemble twins; they have common mechanistic
ackgrounds and common risk factors based on the underlying
ging process, and similar therapeutic strategy to prevent thrombo-
is. However, there are also distinct differences in the pathogenesis
nd the mechanisms of acute events. Therefore, different risk-
tratiﬁcation schemes and different strategies for the prevention
f events are required.
There has not been a comprehensive report examining the
revalence of CAD and the incidence of coronary events in Japanese
atients with AF, and the present study provides important infor-
ation on this issue. The accumulation of these prospective clinical
ata will be essential for the better management of AF patients,
specially from the viewpoint of optimization of anti-thrombotic
reatment.eferences
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